

Levi A Garraway

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8971154/levi-a-garraway-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

22,958
citations

57
h-index

84
g-index

84
ext. papers

29,205
ext. citations

21.9
avg, IF

6.44
L-index

#	Paper	IF	Citations
83	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.. <i>Cancer Cell</i> , 2022 , 40, 524-544.e5	24.3	2
82	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 1174-1193	24.4	67
81	Quantitative Proteomics of the Cancer Cell Line Encyclopedia. <i>Cell</i> , 2020 , 180, 387-402.e16	56.2	210
80	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019 , 10, 4346	17.4	89
79	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in -, and -Mutant Melanomas. <i>Cancer Discovery</i> , 2019 , 9, 526-545	24.4	41
78	Inherited DNA-Repair Defects in Colorectal Cancer. <i>American Journal of Human Genetics</i> , 2018 , 102, 401-414	41	50
77	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018 , 27, 977-987.e4	24.6	241
76	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018 , 173, 624-633.e8	56.2	71
75	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 645-651	36.3	380
74	Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. <i>Molecular Cell</i> , 2018 , 71, 554-566.e7	17.6	40
73	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , 2018 , 8, 1096-1111	24.4	156
72	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018 , 8, 196-215	24.4	228
71	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018 , 175, 984-997.e24	56.2	477
70	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. <i>Neuro-Oncology</i> , 2017 , 19, 774-785	1	37
69	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , 2017 , 19, 787-795	8.1	34
68	Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. <i>Molecular Systems Biology</i> , 2017 , 13, 905	12.2	133
67	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Medicine</i> , 2017 , 9, 34	14.4	1509

66	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. <i>Cancer Discovery</i> , 2017 , 7, 973-983	24.4	65
65	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , 2017 , 14, 37-50	2.2	13
64	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , 2017 , 18, e653-e706	21.7	106
63	Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. <i>Cell Systems</i> , 2017 , 5, 105-118.e9	10.6	27
62	Defining a Cancer Dependency Map. <i>Cell</i> , 2017 , 170, 564-576.e16	56.2	844
61	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017 , 23, 1063-1071	50.5	169
60	IFN γ -Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. <i>Cell</i> , 2017 , 170, 127-141.e15	56.2	104
59	Systematic genomic and translational efficiency studies of uveal melanoma. <i>PLoS ONE</i> , 2017 , 12, e0178139	3.7	21
58	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1134-1147	24.4	81
57	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 820-4	7.3	26
56	Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. <i>Cancer Discovery</i> , 2016 , 6, 914-29	24.4	343
55	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. <i>Clinical Cancer Research</i> , 2016 , 22, 2183-9	12.9	10
54	MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. <i>Science</i> , 2016 , 351, 1214-8	33.3	248
53	Oncologists and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. <i>Genetics in Medicine</i> , 2016 , 18, 1011-9	8.1	84
52	Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E1296-305	11.5	33
51	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016 , 22, 298-305	50.5	775
50	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016 , 351, 1463-9	33.3	1758
49	Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 542-542	2.2	

48	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016 , 1, e87062	9.9	245
47	Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. <i>DMM Disease Models and Mechanisms</i> , 2016 , 9, 811-20	4.1	37
46	Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. <i>Cell Reports</i> , 2016 , 17, 1171-1183	10.6	78
45	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. <i>Cancer Cell</i> , 2016 , 29, 846-858	24.3	160
44	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. <i>Cell Reports</i> , 2016 , 15, 857-865	10.6	422
43	gkmSVM: an R package for gapped-kmer SVM. <i>Bioinformatics</i> , 2016 , 32, 2205-7	7.2	87
42	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016 , 98, 1051-1066	11	107
41	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , 2016 , 128, 1093-100	2.2	78
40	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016 , 8, 79	14.4	109
39	PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. <i>Cancer Research</i> , 2015 , 75, 1944-8	10.1	40
38	Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 5708-13	11.5	78
37	A functional landscape of resistance to ALK inhibition in lung cancer. <i>Cancer Cell</i> , 2015 , 27, 397-408	24.3	123
36	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015 , 5, 1164-1177	24.4	581
35	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2015 , 1, 238-44	13.4	41
34	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015 , 350, 207-211	33.3	1583
33	Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2700-11	6.1	49
32	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015 , 1, 662-7	13.4	53
31	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765

30	Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. <i>JAMA Oncology</i> , 2015 , 1, 653-61	13.4	336
29	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , 2015 , 3, 855-63	12.5	53
28	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015 , 51, 2792-9	7.5	202
27	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. <i>Nature Medicine</i> , 2014 , 20, 682-8	50.5	406
26	Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. <i>Nature Biotechnology</i> , 2014 , 32, 71-5	44.5	92
25	Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature</i> , 2014 , 505, 495-501	50.4	1990
24	RNF43 is frequently mutated in colorectal and endometrial cancers. <i>Nature Genetics</i> , 2014 , 46, 1264-6	36.3	287
23	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , 2014 , 32, 644-52	44.5	205
22	A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. <i>Cancer Discovery</i> , 2014 , 4, 816-27	24.4	338
21	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 660-72	5.1	57
20	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , 2014 , 4, 1140-53	24.4	361
19	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E5564-73	11.5	275
18	Genetic modifiers of EGFR dependence in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 18661-6	11.5	37
17	Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. <i>Cancer Cell</i> , 2014 , 26, 813-825	24.3	216
16	ARID1B is a specific vulnerability in ARID1A-mutant cancers. <i>Nature Medicine</i> , 2014 , 20, 251-4	50.5	243
15	Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. <i>PLoS ONE</i> , 2014 , 9, e101283	3.7	60
14	Lessons from the cancer genome. <i>Cell</i> , 2013 , 153, 17-37	56.2	912
13	Precision oncology: an overview. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1803-5	2.2	229

12	Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution. <i>Blood</i> , 2013 , 122, 596-596	2.2	4
11	High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. <i>Cancer Discovery</i> , 2012 , 2, 82-93	24.4	425
10	Whole-genome sequencing and cancer therapy: is too much ever enough?. <i>Cancer Discovery</i> , 2012 , 2, 766-8	24.4	19
9	Circumventing cancer drug resistance in the era of personalized medicine. <i>Cancer Discovery</i> , 2012 , 2, 214-26	24.4	348
8	Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 680-4	7.1	6
7	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011 , 43, 964-968	36.3	242
6	On or off target: mutations, models, and predictions. <i>Science Translational Medicine</i> , 2010 , 2, 35ps28	17.5	2
5	Inclusion of the ASH1 gene that governs the neuroendocrine differentiation of lung epithelium as an additional prototypic lineage-survival oncogene. <i>Nature Reviews Cancer</i> , 2007 , 7, 68-68	31.3	
4	From integrated genomics to tumor lineage dependency. <i>Cancer Research</i> , 2006 , 66, 2506-8	10.1	26
3	Lineage dependency and lineage-survival oncogenes in human cancer. <i>Nature Reviews Cancer</i> , 2006 , 6, 593-602	31.3	267
2	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. <i>Nature</i> , 2005 , 436, 117-22	50.4	1127
1	Intermediate basal cells of the prostate: in vitro and in vivo characterization. <i>Prostate</i> , 2003 , 55, 206-18	4.2	81